The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
Patrick Falvey
Advertisement
Patrick Falvey is principal consultant 2 of Chemistry Manufacturing and Controls, Sia/LBG.
Articles by Patrick Falvey
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Considerations for Quality Improvement of Cleaning, Disinfection, and Cleaning Validation in Biopharmaceutical Manufacturing, Part II. Biopharmaceutical Non-Sterile Equipment Cleaning
2
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
3
Celebrating 20 Years of HPLC-CAD Technology
4
BioPharm Weekly News Roundup—Week of Oct. 6, 2025
5
